发明名称 RBM3 PROTEIN IN COLORECTAL CANCER PROGNOSTICS
摘要 <p>A method for determining whether a mammalian subject having a malignant melanoma belongs to a first or a second group, wherein the prognosis of subjects of the first group is better than the prognosis of subjects of the second group is provided. The method comprises the steps of: evaluating an amount of RBM3 protein in at least part of a sample earlier obtained from the subject and determining a sample value corresponding to the evaluated amount; comparing said sample value with a predetermined reference value; and if said sample value is higher than said reference value, concluding that the subject belongs to the first group; and if said sample value is lower than or equal to said reference value, concluding that the subject belongs to the second group.</p>
申请公布号 EP2396346(B1) 申请公布日期 2013.04.03
申请号 EP20100705141 申请日期 2010.02.16
申请人 ATLAS ANTIBODIES AB 发明人 UHLEN, MATHIAS;PONTEN, FREDRIK;JIRSTROEM, KARIN
分类号 C07K14/47;G01N33/574 主分类号 C07K14/47
代理机构 代理人
主权项
地址